Clinical Trial

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

Study acronym: ICONIC-PsA 1
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Protocol Amendment History 3 changes
notable Primary completion moved earlier: 2026-07-24 -> 2026-05-25 2026-08-01
notable Primary completion pushed: 2026-05-27 -> 2026-07-24 2026-06-06
minor Completion moved earlier: 2028-11-21 -> 2028-02-04 2026-04-14
Trial Details
NCT Number NCT06878404
Lead Sponsor Janssen Research & Development, LLC
Conditions Arthritis, Psoriatic
Enrollment 552 participants
Start Date 2025-02-21
Primary Completion 2026-05-25 (estimated)
Study Completion 2028-02-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-31